Decision models for distinguishing between clinically insignificant and significant tumors in prostate cancer biopsies: an application of Bayes’ Theorem to reduce costs and improve outcomes

Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weisfield JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate cancer screening trial. N Engl J Med 360(13):1310–1319

Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lojan M, Maattdnen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman U-H, Kojola P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RHN, de Koning HJ, Moss SM, Auvinun A (2014) Screening and prostate cancer mortality: results of the European randomized study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035

Bangma CH, Roemeling S, Schroder (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25(1):3–9

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101(6):374–383

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TLJ, Villers A, Hugosson J, Schroder FH, Zappa M (2015) Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European randomized study of screening for prostate cancer. Eur Urol 68:885–890

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70–98

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232–2241

U.S. Preventive Services Task Force (2008) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185–191

Moyer VA (2012) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157(2):120–134

Drazer MW, Huo D, Eggener SC (2015) National prostate cancer screening rates after the 2012 U.S. Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33(22):2416–2416

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM (2015) Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314(19):2054–2060

Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM (2016) Increasing incidence of metastatic prostate cancer in the United States (2004–2013). Prostate Cancer Prostatic Dis 19:395–397

Ross KS, Carter HB, Pearson JD, Guess HA (2000) Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284(11):1399–1405

Zhang J, Denton BT, Balasubramanian H, Shah ND, Inman BA (2012) Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Mak 32(2):337–349

Underwood DJ, Zhang J, Denton BJ, Shah ND, Inman BA (2012) Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci 15(4):293–309

Bertsimas D, Silberholz J, Trikalinos T (2018) Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening. Health Care Manag Sci 21(1):105–118

Gulati R, Gore JL, Etzioni R (2013) Comparative effectiveness of alternative PSA-based prostate cancer screening strategies. Ann Intern Med 158(3):145–153

Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided trans-rectal core biopsies of the prostate. J Urol 142:71–75

Presti JC Jr, O’Dowd GJ, Miller MC (2003) Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 169(1):125–129

Epstein JI, Walsh PC, Carter HB (2001) Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 57:1112–1116

Boccon-Gibod L (1996) Editorial: significant versus insignificant cancer-can we identify the tigers from the pussycats. J Urol 156:1069–1070

Epstein JI, Walsh PC, Brendler CB (1994a) Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 152:1721–1729

Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994b) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368

Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170:1792–1797

Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 101:2001–2005

Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH (2007) Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177:107–112

Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 54:1306–1313

Chun FK, Haese A, Ahyai SA et al (2008) Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113:701–709

O’Brien BA, Cohen RJ, Ryan A, Senqupta S, Mills J (2011) A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. J Urol 186:1811–1817

Iremashvili V, Soloway SW, Pelaez L, Rosenberg DL, Manoharan M (2013) Comparative validation of nomograms predicting clinically insignificant prostate cancer. J Urol 81:1202–1208

Nguyen CT, Kattan MW (2012) Formalized prediction of clinically significant prostate cancer: is it possible? Asian J Androl 14:349–354

Komai Y, Kawakami S, Numao N, Fujii Y, Saito K, Kubo Y, Koga F, Kumagai J, Yamamoto S, Yonese J, Ishikawa Y, Fukui I, Kihara K (2012) Extended biopsy based on criteria incorporating cumulative cancer length for predicting insignificant prostate cancer. BJU Int 110:E564–E569

Kajikawa K, Kanao K, Kobayashi I, Nishikawa G, Yoshizawa T, Kato Y, Watanabe M, Zennami K, Nakamura K, Sumitomo M (2016) Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer. Int J Urol 23:62–68

Kim TH, Jeon HG, Seo IS et al (2017) Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy. Scand J Urol 51(1):27–32

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, de Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629

Berwick DM, Nolan TW, Whittington J (2008) The triple aim: care, health, and cost. Health Aff 27(3):759–769

Daneshgari F, Taylor GD, Miller GJ, Crawford ED (1995) Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 45:604–609

Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whttemore AS, Schmid H-P (1993) Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(Suppl):933–938

Andreoiu MD, Cheng L (2010) Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 41:781–793

Zeng J, Bauer JJ, Mun SK (2000) Modeling and mapping of prostate cancer. Comput Graph 24:683–694

Tanaka N, Shimada K, Nakagawa Y, Hirao S, Watanabe S, Miyake M, Anai S, Hirayama A, Konishi N, Fujimoto K (2015) The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara urological research and treatment group nomogram. BMC Res Notes 8:689–697

Cooner WH, Mosley BR, Rutherford CL Jr et al (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146–1154

Catalona WJ, Richie JP, Ahmann FR, Hudson M’LA, Scardino PT, Flanigan RC, Dekernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, Macfarlane MT, Southwick PC (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151:1283–1290

Schwartz MJ, Hwang DH, Hung AJ, Han J, McClain JW, Shemtov MM, te AE, Sosa RE, Vaughan ED, Scherr DS (2008) Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy. Cancer 112:1718–1725

Iczkowski KA, Casella G, Seppala RJ, Jones GL, Mishler BA, Qian J, Bostwick DG (2002) Needle core length in sextant biopsy influences prostate cancer detection rate. Urology 59:698–703

Öbeka C, Doğanca T, Erdal S, Erdoğan DH (2012) Core length in prostate biopsy: size matters. J Urol 187:2051–2055

Kanao K, Eastham JA, Scardino P, Reuter VE, Fine SW (2013) Can transrectal needle biopsy be optimized to detect nearly all prostate cancer with a volume of ≥ 0.5 mL? A three dimensional analysis. BJU Int 112:898–904

Jones JS (2007) Saturation biopsy for detecting and characterizing prostate cancer. BJU Int 99:1340–1344

Irani J, Blanchet P, Salomon L, Coloby P, Hubert J, Malavaud B, Mottet N (2013) Is an extended 20-core prostate biopsy more efficient than the standard 12-core? A randomized multicenter trial. J Urol 190:77–83

Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, Wheeler TM, Schlossberg S, Penson DF, Taneja SS (2013) Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol 189:2039–2046

Noguchi M, Deguchi D, Toriwaki J et al (2006) Evaluation of a prostate biopsy strategy for cancer detection using a computer simulation system with virtual needle biopsy for three-dimensional prostate models. Int J Urol 13:1296–1303

Bul M, Delongchamps NB, Steyerberg EW et al (2011) Updating the prostate cancer risk indicator for contemporary biopsy schemes. Can J Urol 18(2):5625–5629